AlloVir Competitors, Revenue, Alternatives and Pricing

Claim your profile


Boston, MA USA
Total Funding:N/A
Lead Investor(s):N/A

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • AlloVir's estimated annual revenue is currently $11M per year.(?)
  • AlloVir's estimated revenue per employee is $155,000

Employee Data

  • AlloVir has 71 Employees.(?)
  • AlloVir grew their employee count by 145% last year.
  • AlloVir currently has 15 job openings.

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The companyᅢᄁ¬ツᆲ¬トᄁs technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVirᅢᄁ¬ツᆲ¬トᄁs technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.